Aberdeen Group plc Raises Stock Holdings in uniQure N.V. $QURE

Aberdeen Group plc increased its stake in shares of uniQure N.V. (NASDAQ:QURE) by 6.9% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 2,939,743 shares of the biotechnology company’s stock after buying an additional 189,029 shares during the quarter. Aberdeen Group plc owned about 5.36% of uniQure worth $171,593,000 at the end of the most recent quarter.

Other hedge funds have also modified their holdings of the company. Jefferies Financial Group Inc. purchased a new position in uniQure in the second quarter valued at about $29,217,000. JPMorgan Chase & Co. boosted its position in uniQure by 471.7% during the 2nd quarter. JPMorgan Chase & Co. now owns 1,807,685 shares of the biotechnology company’s stock worth $25,199,000 after purchasing an additional 1,491,486 shares during the period. Sofinnova Investments Inc. raised its stake in shares of uniQure by 185.5% during the second quarter. Sofinnova Investments Inc. now owns 1,558,356 shares of the biotechnology company’s stock valued at $21,723,000 after purchasing an additional 1,012,585 shares during the period. Balyasny Asset Management L.P. lifted its stake in shares of uniQure by 2,054.1% in the second quarter. Balyasny Asset Management L.P. now owns 536,968 shares of the biotechnology company’s stock worth $7,485,000 after acquiring an additional 512,040 shares in the last quarter. Finally, Ameriprise Financial Inc. boosted its stake in uniQure by 38.6% during the 2nd quarter. Ameriprise Financial Inc. now owns 761,948 shares of the biotechnology company’s stock valued at $10,622,000 after acquiring an additional 212,218 shares during the last quarter. 78.83% of the stock is owned by institutional investors and hedge funds.

uniQure News Summary

Here are the key news stories impacting uniQure this week:

• Positive Sentiment: HC Wainwright reiterated a Buy rating on uniQure, which may provide some analyst support for the stock. Read More.
• Positive Sentiment: Aggregate analyst coverage shows a consensus “Moderate Buy” on QURE, a signal that some sell‑side analysts still view upside. Read More.
• Neutral Sentiment: Profile/feature mentions (e.g., a Time piece listed in feeds) appear unrelated to the securities actions and are unlikely to move the stock materially. Read More.
• Negative Sentiment: Multiple law firms have filed or announced securities‑class actions and investor alerts against uniQure alleging violations of federal securities laws for the period Sept. 24, 2025–Oct. 31, 2025 — several firms (Schall, Rosen, Berger Montague, Kessler Topaz, DJS, Faruqi, Bernstein Liebhard, ClaimsFiler, etc.) are soliciting lead‑plaintiff applications and investigations. This wave of litigation increases legal risk, potential damages, and investor uncertainty. Read More. Read More. Read More.
• Negative Sentiment: At least one notice and media summary links the litigation to an alleged FDA approval delay and a roughly 49% prior stock decline; such factual allegations (if pursued) could prolong volatility, increase settlement risk, and weigh on investor sentiment. Read More.

Insider Activity at uniQure

In other uniQure news, Director Robert Gut sold 25,613 shares of the firm’s stock in a transaction that occurred on Monday, January 12th. The shares were sold at an average price of $24.62, for a total value of $630,592.06. Following the transaction, the director directly owned 32,342 shares of the company’s stock, valued at approximately $796,260.04. This trade represents a 44.19% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Jack Kaye sold 6,390 shares of the stock in a transaction that occurred on Friday, January 9th. The shares were sold at an average price of $27.28, for a total transaction of $174,319.20. Following the completion of the sale, the director owned 20,439 shares in the company, valued at $557,575.92. This represents a 23.82% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Corporate insiders own 4.79% of the company’s stock.

uniQure Price Performance

uniQure stock opened at $20.50 on Friday. The company has a debt-to-equity ratio of 0.23, a quick ratio of 7.12 and a current ratio of 7.12. The firm has a market cap of $1.28 billion, a P/E ratio of -4.67 and a beta of 0.66. The business’s fifty day moving average is $23.37 and its two-hundred day moving average is $29.13. uniQure N.V. has a 52 week low of $7.76 and a 52 week high of $71.50.

Wall Street Analyst Weigh In

A number of brokerages have commented on QURE. Wells Fargo & Company decreased their target price on uniQure from $80.00 to $60.00 and set an “overweight” rating for the company in a research note on Wednesday, November 12th. HC Wainwright reissued a “buy” rating and issued a $70.00 target price on shares of uniQure in a research report on Tuesday, February 10th. Stifel Nicolaus decreased their target price on shares of uniQure from $50.00 to $40.00 and set a “buy” rating for the company in a research note on Thursday, December 11th. Cantor Fitzgerald restated an “overweight” rating on shares of uniQure in a report on Wednesday, January 14th. Finally, Leerink Partners lowered their target price on uniQure from $68.00 to $60.00 and set an “outperform” rating on the stock in a report on Monday, November 10th. Ten research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, uniQure presently has a consensus rating of “Moderate Buy” and an average price target of $58.33.

About uniQure

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.